Patients with atrial fibrillation undergoing percutaneous coronary intervention. Current concepts and concerns: part...

Area of Science:

• Cardiology
• Thrombosis Research
• Pharmacology

Background:

• Atrial fibrillation (AF) and coronary artery disease (CAD) frequently coexist, increasing thrombotic complication risks.
• Thrombus formation differs: coagulation activation in AF versus platelet activation in CAD.
• Antithrombotic prophylaxis is crucial for both conditions, especially during percutaneous coronary intervention (PCI).

Purpose of the Study:

• To review antithrombotic management strategies for patients with concomitant AF and CAD undergoing PCI.
• To discuss the epidemiology and differing pathogenesis of thrombus formation in AF and CAD.
• To evaluate antithrombotic regimens, including triple therapy, balancing stroke and bleeding risks.

Main Methods:

• Review of epidemiological data on coexisting AF and CAD.
• Analysis of the distinct pathophysiological mechanisms of thrombus formation.
• Evaluation of clinical data on various antithrombotic regimens and risk stratification.

Main Results:

• Concomitant AF and CAD necessitate complex antithrombotic strategies, often involving triple therapy (oral anticoagulation plus dual antiplatelet therapy).
• Balancing the risk of stroke and stent thrombosis against major bleeding is paramount.
• Triple therapy is frequently indicated but should be used for the shortest effective duration.

Conclusions:

• Antithrombotic management in AF patients undergoing PCI requires careful consideration of individual stroke and bleeding risks.
• While observational data guide current practice, randomized clinical trials are essential for refining optimal therapeutic approaches.
• Short-term triple therapy is often warranted, emphasizing the need for ongoing research in this complex clinical scenario.